{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:20:42Z","timestamp":1740122442737,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Community Health"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s10900-023-01321-6","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T14:02:16Z","timestamp":1703167336000},"page":"526-534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Access to, Experience with, and Attitudes towards Take Home Naloxone: An Online Survey"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0595-6434","authenticated-orcid":false,"given":"Lara","family":"Schwieger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph Edward","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim P.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fire","family":"Erowid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Cornelison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dabney","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian Patrick","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"1321_CR1","unstructured":"Centers for Disease Control and Prevention (CDC). Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic. https:\/\/emergency.cdc.gov\/han\/2020\/han00438.asp (accessed 5\/25\/2022."},{"key":"1321_CR2","unstructured":"American Medical Association. Issue brief: Nation\u2019s drug-related overdose and death epidemic continues to worsen. https:\/\/www.ama-assn.org\/system\/files\/issue-brief-increases-in-opioid-related-overdose.pdf (accessed 5\/25\/2022."},{"key":"1321_CR3","unstructured":"Ahmad, F. B., Cisewski, J. A., Rossen, L. M., & Sutton, P. (2022). Provisional drug overdose death counts. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm (accessed 10\/14\/."},{"key":"1321_CR4","unstructured":"National Center for Health Statistics (2022). Drug Overdose Deaths in the U.S. Top 100,000 Annually. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2021\/20211117.htm (accessed 10\/15\/."},{"key":"1321_CR5","doi-asserted-by":"publisher","unstructured":"McClellan, C., et al. (Nov 2018). Opioid-overdose laws association with opioid use and Overdose mortality. Addictive Behaviors, 86, 90\u201395. https:\/\/doi.org\/10.1016\/j.addbeh.2018.03.014.","DOI":"10.1016\/j.addbeh.2018.03.014"},{"key":"1321_CR6","unstructured":"Health and Human Services. U.S. Surgeon General\u2019s Advisory on Naloxone and Opioid Overdose. https:\/\/www.hhs.gov\/surgeongeneral\/reports-and-publications\/addiction-and-substance-misuse\/advisory-on-naloxone\/index.html (accessed 5\/25\/2022."},{"key":"1321_CR7","doi-asserted-by":"publisher","unstructured":"Baca, C. T., & Grant, K. J. (2005). Take-home naloxone to reduce heroin death, Addiction, https:\/\/doi.org\/10.1111\/j.1360-0443.2005.01259.x vol.\u00a0100, no. 12, pp.\u00a01823\u20131831, doi: papers3:\/\/publication\/doi\/10.1111\/j.1360-0443.2005.01259.x.","DOI":"10.1111\/j.1360-0443.2005.01259.x"},{"issue":"5","key":"1321_CR8","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s11524-013-9803-1","volume":"Vol. 90","author":"J Strang","year":"2013","unstructured":"Strang, J., Bird, S. M., & Parmar, M. K. B. (2013). Take-home emergency naloxone to prevent heroin Overdose deaths after prison release: Rationale and practicalities for the N-ALIVE randomized trial. J Urban Health, Vol. 90(5), 983\u2013996. https:\/\/doi.org\/10.1007\/s11524-013-9803-1.","journal-title":"J Urban Health"},{"key":"1321_CR9","unstructured":"Food and Drug Administration. FDA approves first generic naloxone nasal spray to treat opioid overdose. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-generic-naloxone-nasal-spray-treat-opioid-overdose (accessed 5\/25\/2022."},{"key":"1321_CR10","doi-asserted-by":"publisher","unstructured":"Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC Guideline for Prescribing Opioids for Chronic Pain\u2013United States, 2016, JAMA, vol.\u00a0315, no. 15, pp.\u00a01624-45, Apr 19 https:\/\/doi.org\/10.1001\/jama.2016.1464.","DOI":"10.1001\/jama.2016.1464"},{"key":"1321_CR11","doi-asserted-by":"publisher","unstructured":"Green, T. C., Heimer, R., & Grau, L. E. (2008). Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States, Addiction, https:\/\/doi.org\/10.1111\/j.1360-0443.2008.02182.x vol.\u00a0103, no. 6, pp.\u00a0979\u2013989, doi: papers3:\/\/publication\/doi\/10.1111\/j.1360-0443.2008.02182.x.","DOI":"10.1111\/j.1360-0443.2008.02182.x"},{"issue":"3","key":"1321_CR12","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s11524-008-9273-z","volume":"Vol. 85","author":"D Kerr","year":"2008","unstructured":"Kerr, D., Dietze, P., Kelly, A. M., & Jolley, D. (2008). Attitudes of Australian heroin users to peer distribution of naloxone for heroin Overdose: Perspectives on intranasal administration. J Urban Health, Vol. 85(3), 352\u2013360. https:\/\/doi.org\/10.1007\/s11524-008-9273-z.","journal-title":"J Urban Health"},{"key":"1321_CR13","doi-asserted-by":"publisher","unstructured":"Khatiwoda, P., Proeschold-Bell, R. J., Meade, C. S., Park, L. P., & Proescholdbell, S. (May-Jun 2018). Facilitators and barriers to Naloxone Kit Use among opioid-dependent patients enrolled in Medication assisted therapy clinics in North Carolina. North Carolina Medical Journal, 79(3), 149\u2013155. https:\/\/doi.org\/10.18043\/ncm.79.3.149.","DOI":"10.18043\/ncm.79.3.149"},{"key":"1321_CR14","doi-asserted-by":"publisher","unstructured":"Strang, J. (2008). Overdose training and take-home naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses, Addiction, https:\/\/doi.org\/10.1111\/j.1360-0443.2008.02314.x vol.\u00a0103, no. 10, pp.\u00a01648\u20131657, doi: papers3:\/\/publication\/doi\/10.1111\/j.1360-0443.2008.02314.x.","DOI":"10.1111\/j.1360-0443.2008.02314.x"},{"key":"1321_CR15","doi-asserted-by":"publisher","unstructured":"McDonald, R., & Strang, J. (2016). Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria, Addiction, vol.\u00a0111, no. 7, pp.\u00a01177-87, Jul https:\/\/doi.org\/10.1111\/add.13326.","DOI":"10.1111\/add.13326"},{"key":"1321_CR16","doi-asserted-by":"publisher","unstructured":"Madah-Amiri, D., Gjersing, L., & Clausen, T. (2019). Naloxone distribution and possession following a large-scale naloxone programme, Addiction, vol.\u00a0114, no. 1, pp.\u00a092\u2013100, Jan https:\/\/doi.org\/10.1111\/add.14425.","DOI":"10.1111\/add.14425"},{"key":"1321_CR17","doi-asserted-by":"publisher","unstructured":"Holland, T. J., Penm, J., Johnson, J., Sarantou, M., & Chaar, B. B. (Dec 3 2020). Stakeholders\u2019 Perceptions of Factors Influencing the Use of Take-Home-Naloxone. Pharmacy (Basel), 8(4). https:\/\/doi.org\/10.3390\/pharmacy8040232.","DOI":"10.3390\/pharmacy8040232"},{"key":"1321_CR18","unstructured":"Drug Enforcement Administration. National Drug Threat Assessment Summary 2020. https:\/\/www.dea.gov\/sites\/default\/files\/2021-02\/DIR-008-21%202020%20National%20Drug%20Threat%20Assessment_WEB.pdf (accessed 5\/25\/2022."},{"key":"1321_CR19","unstructured":"About Erowid. https:\/\/www.erowid.org\/general\/about\/about.shtml (accessed 5\/25\/2022."},{"key":"1321_CR20","doi-asserted-by":"crossref","unstructured":"Benjamini, Y., & Yekutieli, D., The control of the false Discovery rate in multiple testing under dependency. The Annals of Statistics, vol. 29, no. 4, pp. 1165\u20131188, 01 August 2001 2001.","DOI":"10.1214\/aos\/1013699998"},{"key":"1321_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jsat.2016.07.005","volume":"Vol. 69","author":"H Kirane","year":"2016","unstructured":"Kirane, H., et al. (2016). Awareness and attitudes toward Intranasal Naloxone Rescue for Opioid Overdose Prevention. Journal of Substance Abuse Treatment, Vol. 69, 44\u201349. https:\/\/doi.org\/10.1016\/j.jsat.2016.07.005.","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"1321_CR22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/jurban\/jtg032","volume":"Vol. 80","author":"KH Seal","year":"2003","unstructured":"Seal, K. H., et al. (2003). Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin Overdose: A survey of street-recruited injectors in the San Francisco Bay Area. J Urban Health, Vol. 80(2), 291\u2013301. https:\/\/doi.org\/10.1093\/jurban\/jtg032.","journal-title":"J Urban Health"},{"issue":"2","key":"1321_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/jurban\/jti053","volume":"Vol. 82","author":"KH Seal","year":"2005","unstructured":"Seal, K. H., et al. (2005). Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin Overdose death: A pilot intervention study. J Urban Health, Vol. 82(2), 303\u2013311. https:\/\/doi.org\/10.1093\/jurban\/jti053.","journal-title":"J Urban Health"},{"key":"1321_CR24","doi-asserted-by":"publisher","unstructured":"Wagner, K. D. (2010). Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA, Int J Drug Policy, vol.\u00a021, no. 3, pp.\u00a0186\u2009\u2013\u200993, May https:\/\/doi.org\/10.1016\/j.drugpo.2009.01.003.","DOI":"10.1016\/j.drugpo.2009.01.003"},{"key":"1321_CR25","doi-asserted-by":"publisher","unstructured":"National Academies of Sciences, Engineering, and Medicine (2017). Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Washington, DC: The National Academies Press. https:\/\/doi.org\/10.17226\/24781.","DOI":"10.17226\/24781"},{"key":"1321_CR26","doi-asserted-by":"publisher","unstructured":"Lenton, S. R., Dietze, P. M., & Jauncey, M. (2016). Australia reschedules naloxone for opioid overdose, Med J Aust, vol.\u00a0204, no. 4, pp.\u00a0146-7, Mar 7 https:\/\/doi.org\/10.5694\/mja15.01181.","DOI":"10.5694\/mja15.01181"},{"key":"1321_CR27","doi-asserted-by":"publisher","unstructured":"So, R., et al. (Nov-Dec 2020). The status of naloxone in community pharmacies across Canada. Can Pharm J (Ott), 153(6), 352\u2013356. https:\/\/doi.org\/10.1177\/1715163520958435.","DOI":"10.1177\/1715163520958435"},{"issue":"2","key":"1321_CR28","doi-asserted-by":"publisher","first-page":"E","DOI":"10.2196\/jmir.4.2.e13","volume":"4","author":"G Eysenbach","year":"2002","unstructured":"Eysenbach, G., & Wyatt, J. (2002). Using the internet for surveys and health research. Journal of Medical Internet Research, 4(2), E. https:\/\/doi.org\/10.2196\/jmir.4.2.e13.","journal-title":"Journal of Medical Internet Research"},{"key":"1321_CR29","doi-asserted-by":"publisher","unstructured":"Pal, R. (2013). Ketamine is associated with lower urinary tract signs and symptoms, Drug Alcohol Depend, vol.\u00a0132, no. 1\u20132, pp.\u00a0189\u2009\u2013\u200994, Sep 1 https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.02.005.","DOI":"10.1016\/j.drugalcdep.2013.02.005"}],"container-title":["Journal of Community Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10900-023-01321-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10900-023-01321-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10900-023-01321-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T15:06:50Z","timestamp":1711811210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10900-023-01321-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1321"],"URL":"https:\/\/doi.org\/10.1007\/s10900-023-01321-6","relation":{},"ISSN":["0094-5145","1573-3610"],"issn-type":[{"type":"print","value":"0094-5145"},{"type":"electronic","value":"1573-3610"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"assertion":[{"value":"2 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflict of interest. Fire Erowid manages the website where the survey was hosted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}